Cowen & Co. Sticks to Their Hold Rating for Regeneron (REGN)

By Ryan Adsit

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Regeneron (REGNResearch Report), with a price target of $385. The company’s shares opened today at $396.63, close to its 52-week high of $416.49.

According to, Nadeau is a 4-star analyst with an average return of 3.5% and a 41.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $416.08.

See today’s analyst top recommended stocks >>

The company has a one-year high of $416.49 and a one-year low of $281.89. Currently, Regeneron has an average volume of 766.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.